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Università degli Studi di Firenze, Viale G.B. Morgagni, 85, 50134 Firenze, ItalyThe possibility that epithelial–mesenchymal transition (EMT) for numerous developmental processes including mesoderm for-
could contribute to hepatic ﬁbrogenesis in chronic liver diseases
as reported in other organs, particularly the kidney, reinforced
the concept that activated hepatic stellate cells were not the only
key players in the hepatic ﬁbrogenic process and that other cell
types, either hepatic (i.e. portal ﬁbroblast) or extrahepatic (bone
marrow-derived cells and circulating ﬁbrocytes) could contribute
to this process. The possibility of the rapid mobilization of a large
amount of ﬁbrogenic cells by EMT after liver tissue injury made
this phenomenon a relevant and suitable target for anti-ﬁbrogen-
ic strategies. Following an initial enthusiasm for the discovery of
this novel pathway in ﬁbrogenesis and the publication of a sev-
eral highly quoted papers, more recent research has started to
cast serious doubts upon the real relevance of this phenomenon
in human ﬁbrogenetic disorders. The debate on the authenticity
of EMT or at least on its real contribution to the ﬁbrogenic pro-
cess has become very animated, sometimes reaching levels of
‘‘religious’’ integralism. The overall result is a general confusion
on the meaning and on the deﬁnition of several key aspects.
The aim of this article is to analyze and discuss the evidence sup-
porting or confuting this possibility in order to reach reasonable
and useful conclusions.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Epithelial–mesenchymal transition or transformation (EMT) is
deﬁned as a key developmental program characterized by loss
of cell adhesion, repression of E-cadherin expression, and
increased cell mobility [1]. The term ‘‘transition’’ is currently pre-
ferred since it reﬂects in part the reversibility of the process.
Indeed, the phenotypic plasticity afforded by an EMT is character-
ized by the occurrence of the reverse process, i.e. a mesenchy-
mal–epithelial transition (MET), which involves the conversion
of mesenchymal cells to epithelial derivatives. EMT is essentialJournal of Hepatology 20
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was initially highlighted and characterized in cancer develop-
ment and metastasis and, more recently, in chronic inﬂamma-
tory/ﬁbrogenic disorders.
EMTs: different types for different purposes?
Upon EMT, epithelial cells assume a more mesenchymal pheno-
type, characterized by increased cell motility. This possibility does
not seem to be restricted to epithelial cells during development or
to cancer cells but has been shown to occur in wound healing, tis-
sue regeneration, and organ ﬁbrosis. A classiﬁcation has been
recently proposed to distinguish between these different types of
EMT [2]: (a) type 1 EMT, associatedwith implantation, embryo for-
mation, and organ development, is characterized by a program
organized to generate diverse cell types that share common mes-
enchymal phenotypes. In turn, type 1 EMT can generate the pri-
mary mesenchyme that has the potential to subsequently
undergo a MET to generate secondary epithelia; (b) in type 2
EMT, the program begins as part of a repair-associated event that
has been suggested to generate ﬁbroblasts and other related cells
in order to reconstruct tissues following trauma and inﬂammatory
injury. Differently from the other types of EMT, type 2 EMT is asso-
ciatedwith tissue damage and inﬂammation and, accordingly, it is
abrogated once these causative events cease; (c) type 3 EMToccurs
in neoplastic cells that have previously undergone genetic and epi-
genetic changes, speciﬁcally in genes that favor clonal outgrowth
and the development of localized tumors. In this context, EMT is
elicited by several oncogenic pathways (Src, Ras, integrin, Wnt/
beta-catenin and Notch) [3]. In particular, Ras-MAPK has been
shown to activate two related transcription factors known as Snail
and Slug [4]. Both of these proteins are transcriptional repressors of
E-cadherin and their expression induces EMT. Activation of the
phosphatidylinositol 3’ kinase (PI3K)/AKT axis is also emerging as
a central feature of EMT [5]. Other relevant pathways in EMT
observed in the metastatic process include the transcription factor
Twist and FOXC2, an important player during embryonic
development [6,7], as well as the involvement of microRNAs [8].
The possibility that EMT, speciﬁcally type 2 EMT, could
contribute to hepatic ﬁbrogenesis in chronic liver diseases was
suggested by studies that closely followed experimental evidence
obtained in other organs and particularly the kidney [9–11]. This
biological option strengthened the concept that activated hepatic11 vol. 55 j 459–465
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stellate cells (HSC) were not the only key players in the hepatic
ﬁbrogenic process and that other cell types, either hepatic (i.e.
portal ﬁbroblast) or extrahepatic (bone marrow-derived cells
and circulating ﬁbrocytes) could contribute to this process
[12–14]. The possibility of the rapid mobilization of a large
amount of ﬁbrogenic cells by EMT after liver tissue injury made
this phenomenon a relevant and suitable target for anti-ﬁbrogen-
ic strategies. Following an initial enthusiasm for the discovery of
this novel pathway in ﬁbrogenesis and the publication of a sev-
eral highly quoted papers, more recent research has started to
cast serious doubts about the real relevance of this phenomenon
in human ﬁbrogenetic disorders.
The aim of this article is to analyze and discuss the evidence
supporting or confuting this possibility in order to reach reason-
able and useful conclusions.EMT in ﬁbrogenetic disorders: background issues and
‘‘speciﬁc’’ cell markers
Before addressing speciﬁc experimental evidence supporting or
not the occurrence of EMT in hepatic ﬁbrogenesis, there are
two major pieces of background information that need to be
highlighted. The ﬁrst concerns the almost automatic and uncriti-
cal parallels drawn between the morphology and behavior of
locomotory or sedentary cells in vitro and in different pathologi-
cal processes in vivo. In vitro data supporting EMT derive from
cells in a highly artiﬁcial two-dimensional milieu in which there
is no vascular, endocrine, or neurologic contribution. On the other
hand, studies performed in three-dimensional matrices also do
not recapitulate the real tissue complexity and the results are
very much affected by the applied experimental conditions. An
additional technical problem concerns the fact that most of the
in vitro studies are performed with epithelial cells that in most
circumstances belong to transformed cell lines cultured in an
abundance of serum factors conditioning the loss of their epithe-
lial features and the progressive acquisition of ‘‘mesenchymal’’
characteristics.
Within this background, a multitude of studies have shown
that epithelial cells, including hepatocytes, when cultured
in vitro retain epithelial features including polarity and speciﬁc
protein expression (i.e. albumin for hepatocytes), but when
chronically stimulated with TGF-b1 or serum factors acquire a
pattern of gene expression that is somehow typical of myoﬁbro-
blasts in vivo and in the mesenchyme during development
[15–19]. These genes are often represented by Slug, Twist, Snail,
a-SMA, vimentin, desmin, ﬁbroblast-speciﬁc protein 1 (FSP1; also
known as S100A4 and MTS-1), and discoidin domain receptor
tyrosine kinase 2 (DDR2).
Someof thesemarkershavebeenused to identify epithelial cells
that are in themidst of undergoing an EMT associatedwith chronic
inﬂammation. Such cells continue to exhibit epithelial-speciﬁc
morphologyandmolecularmarkers, suchas cytokeratinandE-cad-
herin, but often show the concomitant expression of the ﬁbroblast
speciﬁc protein-1 (FSP-1) anda-SMA. These aspects have beenpro-
posed to represent the intermediate stages of EMT,when epithelial
markers continue to be expressed but newmesenchymal markers
have already been acquired, and, overall, these observations have
led to the notion of the so-called ‘‘partial EMT’’ [2].
A second key issue is the value of different cell markers in
deﬁning cell-lineage and, even more relevant, cell function. The
most widely used marker identifying myoﬁbroblasts is the cyto-460 Journal of Hepatology 201skeletal protein a-SMA that is part of the contractile machinery
and is involved in cell motility. In adult normal tissue a-SMA
expression is mostly restricted to vascular smooth muscle cells,
but in most chronic inﬂammatory and ﬁbrogenic disease states
is often found in myoﬁbroblasts of different derivation, and this
expression is interpreted as an active involvement of these cells
in ﬁbrogenesis (i.e. ‘‘activated myoﬁbroblast’’). Accordingly,
a-SMA cannot be a good lineage marker since its expression is
activated by disease states and, in addition, does not denote func-
tion since a-SMA expression has little or no role in the synthesis
and deposition of ﬁbrillar extracellular matrix (ECM). Regardless
of this, there is supportive evidence that epithelial cells express
intermediate ﬁlaments such as a-SMA and vimentin following tis-
sue injury [20,21]. As it will be further expanded, this is likely due
to the engagement of epithelial cells into an adaptive response to
injury that includes the activation of several new programs of
gene expression leading to the acquisition of a migratory pheno-
type. An additional popular cell marker is the multifunctional cal-
cium binding protein FSP-1 (member of the S100 family) wrongly
deﬁned as ‘‘ﬁbroblast-speciﬁc’’. Indeed, this protein, originally
described in malignant epithelial cells as a facilitator of metasta-
tization by regulating the function of contractile proteins [22,23],
is not ‘‘ﬁbroblast-speciﬁc’’ and is expressed predominantly by
activated macrophages [24–27]. Therefore, although this protein
is expressed in cultured epithelial cells exposed to TGF-b, it cannot
be considered as a marker of myoﬁbroblast or epithelial lineage.
Finally, the use of other proposed markers such as Snail, Twist,
Slug seems to be of limited value since they are readily expressed
by epithelial cells, myoﬁbroblasts, andmacrophages following tis-
sue injury and, although theymay be relevant for cell motility and
activation, do not denote cell lineage.
Overall, in a context of tissue ﬁbrogenesis where type 2 EMT is
supposed to occur, the most appropriate marker of myoﬁbroblast
function in vivo is the synthesis anddeposition of pathological type
I collagens [24,28]. However, the evaluation of this property is not
as easy as it could superﬁcially appear and is mainly hampered by
the fact that collagens are predominantly extracellular proteins.
Several in vitro studies have shown that different types of epithelial
cells, including hepatocytes, activate the Collagen1a1 gene in cul-
ture. Similar ﬁndings have been obtained in leukocytes and endo-
thelial cells [29,30]. However, all these cell types do not generate
Collagen1a1 transcripts in vivo [24,28]. Anadditional interpretative
problem is related to the fact that some cell types and particularly
macrophages are able to internalize ECM with consequent intra-
cellular accumulation of collagen which is not a sign of collagen
synthesis. For example, the combination of FSP-1 and intracellular
collagen positivity in activated macrophages detected in tissue
sections may lead to the wrong identiﬁcation of epithelial cells
undergoing EMT and contributing to ﬁbrogenesis [29].
To summarize these considerations, the expression of several
often wrongly deﬁned ‘‘myoﬁbroblast-speciﬁc’’ markers is rather
irrelevant since the only pathophysiologically relevant feature of
ﬁbrogenic cells, irrespective of their origin, is the synthesis and
deposition of relevant amounts of ﬁbrillar collagen.Developmental rationale for ﬁbrogenic EMT in different
tissues: is there a rationale for the liver?
As alreadymentionedbefore, the epic of EMT in the ﬁbrogenic pro-
cess involving the liver as well as of other organs and tissues was
launched by initial evidence obtained in the kidney [9–11]. In this1 vol. 55 j 459–465
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connection, the rationale for type 2 EMT derives from the develop-
ment paradigmofmesoderm-derivedmesenchymal cells develop-
ing in epithelial cells according to the process called MET. The
entire epithelium of the kidney, including the tubular epithelial
cells, is derived from the intermediatemesodermduring thedevel-
opment of the urogenital systemvia aMET. This represents a pecu-
liar aspect of renal biology: by retaining some imprint of their
mesenchymal origins, kidney epithelial cells may be particularly
prone to return to this state, via the EMT that occurs in response
to inﬂammatory stress and leads to pathologic ﬁbrosis. While this
developmental course is clearly recognized in the kidney, it is not
involved in the development of gastrointestinal organs such as
the liver and the pancreas, where all the epithelial cells have been
shown to derive from the foregut endoderm [31,32] and, in this
context, the mesoderm contribution to the development of the
liver and pancreas seems to be limited to stromal cells including
hepatic and pancreatic stellate cells, respectively [33,34]. There-
fore, a developmental rationale for EMT as a source of myoﬁbro-
blasts in liver and pancreas is at best very limited.The saga of EMT investigation in animal models of liver
ﬁbrosis: what have we learned?
The inadequacy of cell markers for the identiﬁcation of unequivo-
cal EMT in ﬁbrogenic disorders and the criticisms raised against
evidences obtained in vitro promptedmajor efforts to characterize
this potentially relevant phenomenon in animal models of liver
ﬁbrosis. The methodological approach used to overcome the lim-
itation of cell surface or cytosolic cell markers is the so-called
‘‘lineage tracing’’ or ‘‘fatemapping’’, which is based on the concept
that once a heritable marker is activated in vivo, it is permanent
and not inducible. In other words, the marker will be present in
any cell deriving from the labeled cell regardless of differentiation,
proliferation, and migration in the context of tissue injury. How-
ever, the application of this concept is only achievable with a com-
plex methodology potentially bearing pitfalls and even more
complex interpretative issues. For example, the activation of the
heritable marker should be a feature only of the cell type to be
labeled and should not normally occur in disease. In this context,
the most likely candidates to activate a heritable marker are tran-
scription factors that are active developmentally.
Zeisberg and co-workers were the ﬁrst to report in vivo evi-
dence for hepatocyte EMT [35]. These authors employed a meth-
odology to drive the DNA recombinase Cre under the control of a
2.3 Kb fragment of the albumin promoter/enhancer locus in order
to activate the heritable marker LacZ in Rosa26R mice developing
CCl4-induced liver ﬁbrosis, so that all hepatocytes and potentially
derived cells were irreversibly tagged with b-galactosidase. In
this model, recombination was speciﬁc for hepatocytes but was,
however, incomplete. Regardless of this, the main interpretative
issue in this work was related to the sole use of FSP-1 marker
to detect scar forming myoﬁbroblastic cells: although it was evi-
dent that a detectable percentage of LacZ protein b-gal-positive
cells co-expressed FSP-1, there was no conclusive evidence that
these cells were effectively myoﬁbroblasts (absence of a-SMA
positivity, no evidence of collagen production). This last funda-
mental issue was subsequently addressed by Taura and co-work-
ers [28], who employed a similar Alb-Cre transgenic model in the
Rosa26R, LacZ expressing reporter mouse with the additional use
of the Coll-GFP reporter to simultaneously identify collagen-Journal of Hepatology 201producing cells and hepatocyte-derived cells in the injured liver.
The results of this study suggested that FSP-1 positive cells do not
generate collagen in vivo and that collagen producing cells are a-
SMA and PDGF-receptor b-positive. These observations, although
not related to human chronic liver diseases in terms of both
genetic background and injury model strongly argue against the
contribution of hepatocyte EMT to liver tissue ﬁbrosis.
It is a common observation that bile duct basement mem-
branes undergo degradation in ﬁbrogenic liver diseases and that
cholangiocytes, the other major hepatic epithelial cell type,
assume ﬁbroblast-like, non-cuboidal shapes. Therefore, with the
new wave of EMT and liver ﬁbrosis, it became obvious that the
next step was to investigate whether or not biliary cells could
undergo EMT in chronic liver disease. It is well established that
proliferating cholangiocytes within the so-called ‘‘ductular reac-
tion’’ (i.e. ‘‘reactive cholangiocytes’’), detectable in all types of
chronic liver disease, express a variety of pro-ﬁbrogenic growth
factors and cytokines (for example PDGF-B chain, TGF-b1, ET 1,
MCP-1) and are likely to contribute to ﬁbrosis and inﬂammation
by promoting activation, proliferation, and collagen synthesis in
the surrounding pro-ﬁbrogenic cells [36–42]. Nevertheless, the
possibility of a direct contribution of cholangiocytes to ﬁbrosis
via EMT was suggested by the report by Omenetti and co-workers
showing in vitro a complete EMT in an immature cholangiocyte
cell line treated with activated HSC conditioned medium [43].
Concomitantly, other authors reported the co-expression of epi-
thelial and mesenchymal markers in cholangiocytes in human
liver obtained from patients with different types of cholestatic
disease [44,45]. The authenticity of cholangiocyte EMT was
recently challenged with the methodology previously used for
the investigation of hepatocyte EMT. Along these lines, Scholten
and co-workers employed the Cre-Lox technology for lineage
tracing and studied several mouse strains expressing Cre under
cholangiocyte-, HSC-, or FSP-1-speciﬁc promoters in two estab-
lished models of liver ﬁbrosis, i.e. chronic CCl4 intoxication and
common bile duct ligation (BDL) [46]. In this case the fundamen-
tal experiment was tracing the fate of cells expressing K19, a bile
ductular cell-speciﬁc marker, after permanent genetic Cre-medi-
ated labeling of cholangiocytes. The key result of this study was
that, although myoﬁbroblast markers were often found in the
close proximity of the K19 + progeny of cholangiocytes, the two
signals never overlapped in either CCl4 or BDL ﬁbrosis. Based
on these and other observations reported in the paper, the
authors concluded that cholangiocyte EMT does not occur in their
experimental models. Additional data reported in the study by
Scholten and co-workers provided parallel evidence that MET,
i.e. the transition from myoﬁbroblast to cholangiocyte in the spe-
ciﬁc experimental context, is also not likely to occur. This latter
conclusion is equally of high value since, at some point of this
saga, some authors have proposed that, in an ideal perspective
of ‘‘liver cell panplasticity’’, HSC could be transitional cells
derived from epithelial cells that have undergone partial EMT
[47] or even a particular type of oval cell/hepatocyte precursor
[48]. This hypothesis was based, at least in part, on the ﬁnding
of an adult subpopulation of primary rat HSC expressing the pro-
genitor cell marker CD133 and differentiating into either myoﬁ-
broblasts or hepatocytes when cultured under different in vitro
conditions [49]. This latter observation, besides its implications
in the issue of MET, raises additional questions on the homogene-
ity of the HSC population; moreover, the results of the study by
Cassiman and co-workers [50] should also be considered as they1 vol. 55 j 459–465 461
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clearly showed that HSC do not descend from the neural crest but
may derive from multiple sources such as the septum transver-
summesenchyme, the endoderm or the mesothelial liver capsule.
It should be reminded that the methodologies employed in the
‘‘lineage tracing’’ studies bear potential pitfalls. As already high-
lighted in a recent commentary [51], the Cre-Lox system is a very
elegant tool to demonstrate that lineage conversion does occur
but it does not prove conclusively that this does not happen. Going
back to the study by Scholten and co-workers [46], since only 40%
efﬁcacy of Cre-recombinationwas achieved, it is possible that only
a speciﬁc subset of cholangiocytes/ductular cells was traced and,
therefore, it is not possible to exclude that EMTmay have occurred
in the remainingpopulation involved in theductular reaction char-
acterized by a weak or absent K19 expression and potentially
including liver progenitor cells. In order to resolve this important
issue, Chu and co-workers undertook lineage tracing studies using
Alfp-Cre  Rosa26-yellow ﬂuorescent protein (YFP) mice, a model
enabling to track the behavior of virtually all bipotential epithelial
progenitors and their progeny in liver injury [52]. These authors
investigated the co-localization of YFP with the markers such as
S100A4, vimentin, a-SMA, or pro-collagen 1a2 in the BDL (2,4,
and 8 wks), CCl4 (3 wks), and 3,5-diethoxycarbonyl-1,4-dihydro-
collidine (DDC;2and3wks)modelsof liverﬁbrosis. Innocase, they
found evidence of co-localization although the above ‘‘mesenchy-
mal’’ markers were abundantly present in the peribiliary regions.
Therefore, these data add additional evidence against the possible
transformation of cholangiocytes and hepatocytes into ﬁbrogenic
cells. In any case, it is important to note that the evaluation time-
frame in anymousemodel is very shortwhen compared to theﬁbr-
ogenic process occurring in human liver diseases and that mouse
models do not display reactive bile ducts with features identical
to those present in human disease.
To conclude this paragraph, it is relevant to delineate the cur-
rent advancement in injury activated EMT in the kidney, the
organ where EMT was ﬁrst described and where there is indeed
the greatest developmental rationale for this process. Using two
distinct epithelial cell-speciﬁc drivers, two distinct reporters
and two different models of renal ﬁbrosis, Humphreys and co-
workers found no evidence that epithelial cells becomemyoﬁbro-
blasts in vivo [25]. In addition, this study highlighted the possibil-
ity that in the kidney all myoﬁbroblasts derive from a discrete
population of PDGFRb+/CD73+ perivascular pericytes that are
derived from the metanephric mesenchyme and show similari-
ties with stellate cells of the liver and pancreas [53].The concept of EMT in organ ﬁbrosis and cancer: need for a
more ﬂexible interpretation
The complexity of EMT and its recognition as a relevant biological
phenomenon in organ ﬁbrosis and cancer requires a more ﬂexibleFig. 1. Hypothesis of the ‘‘redox-based escapemechanism fromdeath’’ to explain the a
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Journal of Hepatology 201and somehow compromising interpretation in order to ﬁt into a
logical scheme. Indeed, even in cancer development and metasta-
sis, the occurrence of EMT is currently extensively challenged
[54]. In this context it is argued that disorderly differentiation,
loss of cell polarity, loss of lineage speciﬁc or tissue speciﬁc cyto-
logic features, and acquisition of a migratory/invasive phenotype
are typical aspects of carcinoma. In other words, what is called
EMT is simply the result of a genetic reprograming of cancer cells
aimed at ensuring one of the fundamental aspects of cancer
which is cell motility and invasion. The acquisition of cell mor-
phology and the expression of cytoskeletal and surface proteins
involved in cell motility typical of mesenchymal cells does not
transform a cancer cell into a myoﬁbroblast. Accordingly, EMT
in cancer biology is not necessarily seen as a phenomenon where
cancer cells differentiate into myoﬁbroblasts to create a tumor-
associated ﬁbrotic stroma. This latter is mostly created by the
recruitment and activation of local myoﬁbroblasts and circulating
ﬁbrocytes in response to soluble factors released by cancer cells
and by the disruption of the normal ECM caused by membrane-
anchored or secreted metalloproteases in the process of cancer
invasion [55,56].
In the injury-activated EMT described in chronic ﬁbrogenic
disorders, epithelial cells are likely to undergo a similar genetic
reprograming which is not caused by genetic mutations typical
of cancer but rather due to an adaptive response to injury and
to the changes occurring in the milieu of a chronically damaged
tissue. As a consequence, epithelial cells acquire features allow-
ing the acquisition of cell motility. When the occurrence of these
‘‘transition’’ features is evaluated with the expression of cell
markers classically but unreliably attributed to myoﬁbroblasts,
the most likely result is to reach the even more unreliable conclu-
sion that epithelial cells have ‘‘cosmetically’’ transformed into
pro-ﬁbrogenic cells. In this framework, the lack of a convincing
demonstration of active collagen synthesis remains a critical
point supporting the unreliability of this conclusion. Now, a spon-
taneous question arises: why non-transformed epithelial cells in
a context of tissue injury should become motile and ‘‘escape’’
from the original epithelial lining? A possible hypothesis could
derive from the so-called ‘‘redox-based escape mechanism from
death’’ which has been shown to govern crucial steps of the met-
astatic process [57]. This adaptive response is now recognized to
occur also in non-transformed epithelial cells in a context of
inﬂammation, hypoxia, and oxidative stress. Overall, this process
can be viewed as an integrated ‘‘escape program’’ from a hostile
microenvironment mainly triggered by redox changes but also
by the presence of an altered ECM composition and high concen-
trations of growth factors and cytokines involved in the chronic
wound healing reaction. The program is characterized by changes
in cell metabolism and cell motility aimed at promoting pro-
survival choices and escape from oxidative damage (Fig. 1A).
The acquisition of the motile phenotype implies adequatecquisition of amigratory phenotype of hepatocytes in a context of tissue injury.
eating a hostile microenvironment. In some hepatocytes, this leads to an epigenetic
tivation of aerobic glycolysis, and survival pathways. The acquisition of the motile
ins such as a-SMA and vimentin, the polarization of cytoskeletal structures to the
rough an increased expression and activity of membrane-anchored or secreted
he lining,motility is ensuredmostly byPI-3K/AKT signaling, integrin clustering, and
s the activation of a degradative potential toward these components. In this context,
vement, is also a key factor ensuring resistance to anoikis, a formof programmed cell
. (B) The possible ﬁnal outcomes of the escape process are basically two: themotile
ard the original lining phenotype or, in the presence of a diffuse and long-lasting
loses the resistance to anoikis with the consequent induction of apoptosis.
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Key Points  
Epithelial-mesenchymal transition or transformation 
(EMT) is defined as a key developmental program 
characterized by loss of cell adhesion, repression of E-
cadherin expression, and increased cell mobility. The 
concept of EMT involves phenotypic plasticity and imply 
the occurrence of the reverse process, i.e. a 
mesenchymal-epithelial transition (MET).  
Three types of EMT have been proposed: type 1, typical 
of development, type 2, occurring in chronic fibrogenic 
disorders, and type 3, characteristic of cancer and 
metastasis.  
The occurrence of EMT relies mostly on the expression 
of cell markers often believed  to be exclusive of 
myofibroblasts. However, in a context of tissue 
fibrogenesis where type 2 EMT is supposed to occur, the 
most appropriate marker of myofibroblast function in vivo
is the synthesis and deposition of pathological type I 
collagens.  
Several in vitro studies have shown that different types of 
epithelial cells, including hepatocytes, activate the 
Collagen1a1 gene in culture. Similar findings have been 
obtained in leukocytes and endothelial cells. However, all 
these cell types do not generate Collagen1a1 transcripts 
in vivo. 
The methodological approach used to overcome the 
limitation of cell surface or cytosolic cell markers is the 
so-called “lineage tracing” or “fate mapping”,  which is 
based on the concept that once a heritable marker is 
activated in vivo, it is permanent and not inducible. 
In their complex, studies employing this methodological 
approach  have documented, in different animal models 
of liver fibrogenesis,  that some hepatocytes or 
cholangiocytes acquire “mesenchymal markers” 
implicated in cell motility and survival,  but are not 
involved in active fibrillar ECM deposition and, therefore, 
cannot be considered pro-fibrogenic cells. 
Overall, the most evident feature of EMT is the 
acquisition of a motile phenotype by epithelial cell in 
injured tissue. Hypothetically this could be viewed as an 
integrated “escape program" from a hostile 
microenvironment mainly triggered by redox changes but 
also by the presence of an altered ECM composition and 
high concentrations of growth factors and cytokines 
involved in the chronic wound healing reaction. The 
program is characterized by  changes in cell metabolism 
and cell motility aimed at promoting pro-survival choices 
and escape from oxidative damage.  
The escape program has two possible two outcomes:  
the motile epithelial cell reaches a less hostile 
microenvironment and undergoes a reprogramming 
towards the original lining phenotype or, in the presence 
of a diffuse and long-lasting hostile milieu,  the newly 
acquired “escaping” features progressively run out and 
the cell undergoes apoptosis. 
In both cases there is a clear pathophysiological 
advantage compared to the fate of non escaping cells, 
whose most likely fate is to undergo cell necrosis with 
further release of reactive oxygen species and other pro-
fibrogenic and pro-inflammatory molecules.  
Accordingly, what has been defined type 2 EMT, could 
be a process aimed at limiting fibrogenesis rather than 
being a pro-fibrogenic event.  
Reviewcytoskeletal reorganization with the expression of proteins such
as a-SMA and vimentin, the polarization of cytoskeletal struc-
tures to the leading edge of movement, integrin clustering and
recycling associated with increased afﬁnity for the surrounding
ECM components, and the activation of a degradative potential464 Journal of Hepatology 201toward these components. This latter feature involves an
increased expression and activity of membrane-anchored or
secreted metalloproteases, urokinase, heparanase, and matrilysin.
In this context, integrin activation through ECM-cell contacts, in
addition to being indispensable for cell movement, is also a key
factor ensuring resistance to anoikis, a form of programmed cell
death which is induced by anchorage-dependent cells detaching
from the surrounding ECM. The possible ﬁnal outcomes of the
escape process are basically two (Fig. 1B): (a) the motile epithelial
cell reaches a less hostile microenvironment and undergoes a rep-
rograming toward the original lining phenotype (a possibility
that, according to the above mentioned ‘‘cosmetic’’ interpretation
is viewed as MET), or (b) in the presence of a diffuse and long-
lasting hostile milieu, the newly acquired ‘‘escaping’’ features
progressively run out and the cell loses the resistance to anoikis
with the consequent induction of apoptosis. In both cases there
is a clear pathophysiological advantage compared to the fate of
non-escaping cells, whose most likely fate is to undergo cell
necrosis with further release of reactive oxygen species and other
pro-ﬁbrogenic and pro-inﬂammatory molecules [58]. Accord-
ingly, what has been deﬁned type 2 EMT could be a process aimed
at limiting ﬁbrogenesis rather than being a pro-ﬁbrogenic event.
In conclusion, the knowledge relative to the discovery, charac-
terization, and interpretation of what is deﬁned as EMT in chronic
ﬁbrogenic disorders of the liver represents a scientiﬁc treasure
that has prompted discussion, animated debates and has
ultimately provided further maturity in this ﬁeld of research. Def-
initely, there is now need for a more insightful analysis of the real
pathophysiological meaning of these observations beyond their
superﬁcial or ‘‘cosmetic’’ features.Conﬂict of interest
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